HomeEquine Research BankVet OphthalmolSubconjunctival autologous muscle-derived mesenchymal stem c...

Veterinary ophthalmology2023; doi: 10.1111/vop.13175

Subconjunctival autologous muscle-derived mesenchymal stem cell therapy: A novel, minimally invasive approach for treating equine immune-mediated keratitis.

Narinx, F
·
Sauvage, A
·
Ceusters, J
·
Grulke, S
·
Serteyn, D
·
Monclin, S

Abstract: To establish the safety of subconjunctival injections of autologous muscle-derived mesenchymal stem cells (mdMSCs) in healthy horses and to evaluate their effect in four horses (six eyes) with severe chronic equine immune-mediated keratitis (IMMK) that was unresponsive to medical treatments. Methods: MdMSCs were cultured from minimally invasive muscle biopsies. In the safety group, four healthy horses received two subconjunctival injections of 2.5 and 5 million cells, respectively, at 1-month interval, to the same eye. Ocular side effects were monitored for 1 month following each injection. In the treatment group, six eyes received four to seven subconjunctival mdMSCs injections (2.5 or 5 million cells per injection) every 4 weeks, approximatively. Medical treatment was discontinued 1 week before and throughout the entire treatment period. A scoring system was used to assess the evolution of the ocular lesions. Results: In the safety group, all horses exhibited mild to moderate chemosis and conjunctival hyperemia at the injection site, lasting 24-48 h. In the treatment group, all eyes initially responded positively to therapy, with a reduction in lesion scores observed after the first injection. Four eyes achieved control of the lesions with repeated injections during the 9.2 months of follow-up. Conclusions: The first subconjunctival injection of mdMSCs resulted in improvement of the ocular lesions. Repeated injections were found to be safe, minimally invasive and showed promise in managing refractory cases of equine IMMK. Further studies are warranted to demonstrate the long-term benefits of these injections and to optimize the therapeutic protocol.

Get Full Text

Publication Date: 2023-12-10 PubMed ID: 38071501DOI: 10.1111/vop.13175Google Scholar: Lookup

The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.

Facebook X LinkedIn Email

Summary
Cite This
Publication
Affiliations
References
Citations

Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article presents results of a safety study and a treatment study on the use of autologous muscle-derived mesenchymal stem cells (mdMSCs) for treating a condition in horses called immune-mediated keratitis (IMMK), that was resistant to standard medical treatments. The research concluded that the injections of stem cells showed promise in controlling the disease, while causing only minor temporary side effects.

Research Methods

The researchers obtained mesenchymal stem cells (MSCs) from muscle biopsies done in a minimally invasive fashion from the same horses that were to be treated. They cultured these cells to obtain enough for several injections.
In the safety phase of the study, four healthy horses were given two subconjunctival injections of the cultured mdMSCs (2.5 and 5 million cells in each injection), one month apart, in the same eye.
Any ocular side effects (reactions in the eye to the injections) were monitored for a month after each injection.
In the treatment phase of the study, four horses with a total of six eyes affected by severe chronic IMMK that had not responded to other treatments, were given four to seven subconjunctival injections of the cultured mdMSCs, approximately every 4 weeks. The horses in this phase of the study were not given any other medical treatment for one week before and during the entire period of the stem cell injections.
The researchers developed a scoring system to monitor the progress of the ocular lesions in each eye.

Results and Findings

In the safety study, each of the horses experienced mild to moderate chemosis (swelling of the membrane lining the eyelids and surface of the eye) and conjunctival hyperemia (excess blood flow in the conjunctiva, the clear tissue covering the white part of the eye), which lasted between 24 to 48 hours.
In the treatment study, all the treated eyes showed an initial positive response with a reduction in the scores of the lesions after the first injection. After repeated injections over 9.2 months of follow-up, four eyes of the horses showed a continued decrease in the lesions.

Conclusions

The first injection of the cultured mdMSCs resulted in an improvement in ocular lesions. Repeated injections were found to be safe and minimally invasive.
The results of the study may present a promising option for managing refractory (resistant to treatment) cases of equine IMMK.
The research paper concludes that further studies are required to determine the long-term benefits of these injections and to develop an optimized therapeutic protocol.

Cite This Article

APA

Narinx F, Sauvage A, Ceusters J, Grulke S, Serteyn D, Monclin S. (2023). Subconjunctival autologous muscle-derived mesenchymal stem cell therapy: A novel, minimally invasive approach for treating equine immune-mediated keratitis. Vet Ophthalmol. https://doi.org/10.1111/vop.13175

Publication

Veterinary ophthalmology

ISSN: 1463-5224

NlmUniqueID: 100887377

Country: England

Language: English

Researcher Affiliations

Narinx, Florine

Department of Clinical Sciences, Companion and Equine Animals, Ophthalmology, Veterinary Teaching Hospital of the University of Liu00e8ge, University of Liu00e8ge, Liu00e8ge, Belgium.

Sauvage, Auru00e9lie

Department of Clinical Sciences, Companion and Equine Animals, Ophthalmology, Veterinary Teaching Hospital of the University of Liu00e8ge, University of Liu00e8ge, Liu00e8ge, Belgium.

Ceusters, Justine

Center for Oxygen Research and Development, Institute of Chemistry, University of Liu00e8ge, Liu00e8ge, Belgium.

Grulke, Sigrid

Department of Clinical Sciences, Equine Surgery, Veterinary Teaching Hospital of the University of Liu00e8ge, University of Liu00e8ge, Liu00e8ge, Belgium.

Serteyn, Didier

Center for Oxygen Research and Development, Institute of Chemistry, University of Liu00e8ge, Liu00e8ge, Belgium.
Department of Clinical Sciences, Equine Surgery, Veterinary Teaching Hospital of the University of Liu00e8ge, University of Liu00e8ge, Liu00e8ge, Belgium.

Monclin, Su00e9bastien

Department of Clinical Sciences, Companion and Equine Animals, Ophthalmology, Veterinary Teaching Hospital of the University of Liu00e8ge, University of Liu00e8ge, Liu00e8ge, Belgium.

References

This article includes 34 references

Brooks DE, Matthews A, Clode AB. Disease of the cornea. In: Gilger BC, ed. Equine Ophthalmology. 3th ed. Wiley-Blackwell; 2017:253-368.
Matthews A, Gilger B. Equine immune-mediated keratopathies. Equine Vet J. 2010;37:31-37.
Pate D, Clode A, Olivry T, Cullen J, Salmon J, Gilger B. Immunohistochemical and immunopathologic characterization of superficial stromal immune-mediated keratitis in horses. Am J Vet Res. 2012;73:1067-1073.
Gilger B, Michau T, Salmon J. Immune-mediated keratitis in horses: 19 cases (1998-2004). Vet Ophthalmol. 2005;8:233-239.
Gilger BC, Stoppini R, Wilkie DA, etu00a0al. Treatment of immune-mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices. Vet Ophthalmol. 2014;1:23-30.
Dieterman E, Hermans H, Slenter I, Kuijpers N, Grinwis G, Boevu00e9 M. Outcome of superficial keratectomy without conjunctival graft as a surgical technique for immune-mediated keratitis in horses: four cases. Equine Vet Edu. 2022;34:323-330.
Ghiasi M, Jadidi K, Hashemi M, Zare H, Salimi A, Aghamollaei H. Application of mesenchymal stem cells in corneal regeneration. Tissue Cell. 2021;73:101600.
Cejka C, Holan V, Trosan P, Zajicova A, Javorkova E, Cejkova J. The favorable effect of mesenchymal stem cell treatment on the antioxidant protective mechanism in the corneal epithelium and renewal of corneal optical properties changed after alkali burns. Oxid Med Cell Longev. 2016;4:1-12.
Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med. 2012;4:1-12.
Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev. 2014;23:1258-1265.
Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419-427.
Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;4:653-664.
Zakirova EY, Valeeva AN, Aimaletdinov AM, etu00a0al. Potential therapeutic application of mesenchymal stem cells in ophthalmology. Exp Eye Res. 2019;189:107863.
Davis AB, Schnabel LV, Gilger BC. Subconjunctival bone marrow-derived mesenchymal stem cell therapy as a novel treatment alternative for equine immune-mediated keratitis: a case series. Vet Ophthalmol. 2019;22:674-682.
Frisbie DD, Smith RK. Clinical update on the use of mesenchymal stem cells in equine orthopaedics. Equine Vet J. 2010;42:86-89.
Fortier LA, Travis AJ. Stem cells in veterinary medicine. Stem Cell Res Ther. 2011;2:9-15.
Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of adult mesenchymal stem cells applicable for musculoskeletal applications - a systematic review of the literature. Open Orthop J. 2011;5:242-248.
Radtke CL, Nino-Fong R, Esparza Gonzalez BP, Stryhn H, McDuffee LA. Characterization and osteogenic potential of equine muscle tissue- and periosteal tissue-derived mesenchymal stem cells in comparison with bone marrow- and adipose tissue-derived mesenchymal stem cells. Am J Vet Res. 2013;74:790-800.
Ceusters J, Lejeune JP, Sandersen C, Niesten A, Lagneaux L, Serteyn D. From skeletal muscle to stem cells: an innovative and minimally-invasive process for multiple species. Sci Rep. 2017;71:696.
Eaton JS, Miller PE, Bentley E, Thomasy SM, Murphy CJ. The SPOTS system: an ocular scoring system optimized for use in modern preclinical drug development and toxicology. J Ocul Pharmacol Ther. 2017;33:718-734.
Zhang L, Coulson-Thomas VJ, Ferreira TG, Kao WW. Mesenchymal stem cells for treating ocular surface diseases. BMC Ophthalmol. 2015;15:155.
Zhou Y, Chen Y, Wang S, Qin F, Wang L. MSCs helped reduce scarring in the cornea after fungal infection when combined with anti-fungal treatment. BMC Ophthalmol. 2019;19:226.
Song HB, Park SY, Ko JH, etu00a0al. Mesenchymal stromal cells inhibit inflammatory Lymphangiogenesis in the cornea by suppressing macrophage in a TSG-6-dependent manner. Mol Ther. 2018;26:162-172.
Kossl J, Bohacova P, Hermankova B, Javorkova E, Zajicova A, Holan V. Antiapoptotic properties of mesenchymal stem cells in a mouse model of corneal inflammation. Stem Cells Dev. 2021;30:418-427.
Dechu00eane L, Colin M, Demazy C, etu00a0al. Characterization of the proteins secreted by equine muscle-derived mesenchymal stem cells exposed to cartilage explants in osteoarthritis model. Stem Cell Rev Rep. 2023;19:550-567.
Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response inu00a0vitro. Stem Cell Res Ther. 2014;5:13.
Pezzanite LM, Fortier LA, Antczak DF, etu00a0al. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses inu00a0vivo. Stem Cell Res Ther. 2015;6:1.
Galindo S, de la Mata A, Lu00f3pez-Paniagua M, etu00a0al. Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art. Stem Cell Res Ther. 2021;12:60.
Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:130763.
Di G, Du X, Qi X, etu00a0al. Mesenchymal stem cells promote diabetic corneal epithelial wound healing through TSG-6-dependent stem cell activation and macrophage switch. Invest Ophthalmol Vis Sci. 2017;58:4344-4354.
Shukla S, Mittal SK, Foulsham W, etu00a0al. Therapeutic efficacy of different routes of mesenchymal stem cell administration in corneal injury. Ocul Surf. 2019;17:729-736.
Ghazaryan E, Zhang Y, He Y, etu00a0al. Mesenchymal stem cells in corneal neovascularization: comparison of different application routes. Mol Med Rep. 2016;14:3104-3112.
Yao L, Li ZR, Su WR, etu00a0al. Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn. PLoS ONE. 2012;7:e30842.
Zhang N, Luo X, Zhang S, etu00a0al. Subconjunctival injection of tumor necrosis factor-u03b1 pre-stimulated bone marrow-derived mesenchymal stem cells enhances anti-inflammation and anti-fibrosis in ocular alkali burns. Graefes Arch Clin Exp Ophthalmol. 2021;259:929-940.

Citations

This article has been cited 0 times.